Related Experiment Videos
Wiskott-Aldrich syndrome carrier detection with the hypervariable marker M27 beta
G de Saint Basile1, L D Notarangelo, C Bonaiti-Pellié
1INSERM U, 132, Hôpital des Enfants-Malades, Paris, France.
Human Genetics
|May 1, 1992
Summary
Researchers identified a new marker, M27 beta, to accurately determine X-chromosome inactivation patterns in Wiskott-Aldrich syndrome (WAS) families. This improves genetic counseling for carriers, even without affected males.
Area of Science:
- Genetics
- Molecular Biology
- Immunology
Background:
- Wiskott-Aldrich syndrome (WAS) is an X-linked immunodeficiency.
- Obligate carriers of WAS exhibit nonrandom X-chromosome inactivation.
- Previous methods for determining X-inactivation patterns were limited by probe polymorphism.
Purpose of the Study:
- To evaluate the utility of the M27 beta marker for X-chromosome inactivation analysis in normal females and WAS families.
- To compare the M27 beta marker with established probes (PGK and HPRT) for methylation differences.
- To assess the M27 beta marker's effectiveness in segregation analysis for WAS kindreds.
Main Methods:
- Analysis of X-chromosome inactivation patterns using the M27 beta marker (DXS255 locus) in normal females and WAS families.
- Comparison of M27 beta results with methylation patterns from PGK and HPRT gene probes.
- Segregation analysis of WAS families using M27 beta and related markers.
Main Results:
- Normal females exhibited random X-chromosome inactivation.
- Complete correlation was observed between the M27 beta probe and the PGK/HPRT probes.
- M27 beta marker facilitated accurate segregation analysis in WAS families, consistent with X-inactivation data.
Conclusions:
- The M27 beta marker is a valuable tool for determining X-chromosome inactivation patterns.
- This marker enhances genetic counseling capabilities for Wiskott-Aldrich syndrome families, including those with no surviving males.
- M27 beta provides a basis for genetic counseling in the majority of WAS families.